|
1
|
Mattiuzzi C, Sanchis-Gomar F and Lippi G:
Concise update on colorectal cancer epidemiology. Ann Transl Med.
7(609)2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Rawla P, Sunkara T and Barsouk A:
Epidemiology of colorectal cancer: Incidence, mortality, survival,
and risk factors. Prz Gastroenterol. 14:89–103. 2019.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Lohsiriwat V, Chaisomboon N and
Pattana-Arun J: Current colorectal cancer in Thailand. Ann
Coloproctol. 36:78–82. 2020.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Tiankanon K, Aniwan S and Rerknimitr R:
Current status of colorectal cancer and its public health Burden in
Thailand. Clin Endosc. 54:499–504. 2021.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Koncina E, Haan S, Rauh S and Letellier E:
Prognostic and predictive molecular biomarkers for colorectal
cancer: Updates and challenges. Cancers (Basel).
12(319)2020.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Sawicki T, Ruszkowska M, Danielewicz A,
Niedźwiedzka E, Arłukowicz T and Przybyłowicz KE: A review of
colorectal cancer in terms of epidemiology, risk factors,
development, symptoms and diagnosis. Cancers (Basel).
13(2025)2021.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Pagliaroli L and Trizzino M: The
evolutionary conserved SWI/SNF Subunits ARID1A and ARID1B are key
modulators of pluripotency and cell-fate determination. Front Cell
Dev Biol. 9(643361)2019.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Schaefer IM and Hornick JL: SWI/SNF
complex-deficient soft tissue neoplasms: An update. Semin Diagn
Pathol. 38:222–231. 2021.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Lin C, Song W, Bi X, Zhao J, Huang Z, Li
Z, Zhou J, Cai J and Zhao H: Recent advances in the ARID family:
Focusing on roles in human cancer. Onco Targets Ther. 7:315–324.
2014.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Sun J and Cheng NS: Comprehensive
landscape of ARID family members and their association with
prognosis and tumor microenvironment in hepatocellular carcinoma. J
Immunol Res. 2022(1688460)2022.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Aso T, Uozaki H, Morita S, Kumagai A and
Watanabe M: Loss of ARID1A, ARID1B, and ARID2 expression during
progression of gastric cancer. Anticancer Res. 35:6819–6827.
2015.PubMed/NCBI
|
|
12
|
Fantone S, Mazzucchelli R, Giannubilo SR,
Ciavattini A, Marzioni D and Tossetta G: AT-rich interactive domain
1A protein expression in normal and pathological pregnancies
complicated by preeclampsia. Histochem Cell Biol. 154:339–346.
2020.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Wei XL, Wang DS, Xi SY, Wu WJ, Chen DL,
Zeng ZL, Wang RY, Huang YX, Jin Y, Wang F, et al: Clinicopathologic
and prognostic relevance of ARID1A protein loss in colorectal
cancer. World J Gastroenterol. 20:18404–18412. 2014.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Khursheed M, Kolla JN, Kotapalli V, Gupta
N, Gowrishankar S, Uppin SG, Sastry RA, Koganti S, Sundaram C,
Pollack JR and Bashyam MD: ARID1B, a member of the human SWI/SNF
chromatin remodeling complex, exhibits tumour-suppressor activities
in pancreatic cancer cell lines. Br J Cancer. 108:2056–2062.
2013.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Li K, Wang B and Hu H: Research progress
of SWI/SNF complex in breast cancer. Epigenetics Chromatin.
17(4)2024.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Sato E, Nakayama K, Razia S, Nakamura K,
Ishikawa M, Minamoto T, Ishibashi T, Yamashita H, Iida K and Kyo S:
ARID1B as a potential therapeutic target for ARID1A-mutant ovarian
clear cell carcinoma. Int J Mol Sci. 19(1710)2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Wang B, Xie H, Ma C, Zhang G, Gan H, Wang
Q, Liu X, Zhu Y, Zhu Y, Shi G, et al: Expression of ARID1B is
associated with poor outcomes and predicts the benefit from
adjuvant chemotherapy in bladder urothelial carcinoma. J Cancer.
8:3490–3497. 2017.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Moreno T, Monterde B, González-Silva L,
Betancor-Fernández I, Revilla C, Agraz-Doblas A, Freire J, Isidro
P, Quevedo L, Blanco R, et al: ARID2 deficiency promotes tumor
progression and is associated with higher sensitivity to
chemotherapy in lung cancer. Oncogene. 40:2923–2935.
2021.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Cajuso T, Hänninen UA, Kondelin J, Gylfe
AE, Tanskanen T, Katainen R, Pitkänen E, Ristolainen H, Kaasinen E,
Taipale M, et al: Exome sequencing reveals frequent inactivating
mutations in ARID1A, ARID1B, ARID2 and ARID4A in microsatellite
unstable colorectal cancer. Int J Cancer. 135:611–623.
2014.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Duan Y, Tian L, Gao Q, Liang L, Zhang W,
Yang Y, Zheng Y, Pan E, Li S and Tang N: Chromatin remodeling gene
ARID2 targets cyclin D1 and cyclin E1 to suppress hepatoma cell
progression. Oncotarget. 7:45863–45875. 2016.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Aluksanasuwan S, Somsuan K, Wanna-Udom S,
Roytrakul S, Morchang A, Rongjumnong A and Sakulsak N: Proteomic
insights into the regulatory function of ARID1A in colon cancer
cells. Oncol Lett. 28(392)2024.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Angelico G, Attanasio G, Colarossi L,
Colarossi C, Montalbano M, Aiello E, Di Vendra F, Mare M, Orsi N
and Memeo L: ARID1A mutations in gastric cancer: A review with
focus on clinicopathological features, molecular background and
diagnostic interpretation. Cancers. 16(2062)2024.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Jin M, Xu S, Li J, Li L and Tang C: Role
of ARID1A in the regulation of human trophoblast migration and
invasion. Reprod Sci. 29:2363–2373. 2022.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Wanna-Udom S, Aluksanasuwan S, Somsuan K,
Mongkolwat W and Sakulsak N: ARID1A overexpression inhibits
colorectal cancer cell migration through the regulation of
epithelial-mesenchymal transition. Mol Med Rep.
30(201)2024.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Zhu G, Liu J, Li Y, Huang H, Chen C, Wu D,
Cao P, Su L, Wang Y, Zhang H, et al: ARID1B deficiency leads to
impaired DNA damage response and activated cGAS-STING pathway in
non-small cell lung cancer. J Cancer. 15:2601–2612. 2024.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Shen Y, Chen W, Fu C, Liu X, Miao J, Li J,
Li N and Hang D: Polygenic risk score, healthy lifestyle score, and
colorectal cancer risk: A prospective cohort study. Cancer
Epidemiol Biomarkers Prev. 34:290–297. 2025.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Guan X, Cai M, Du Y, Yang E, Ji J and Wu
J: CVCDAP: An integrated platform for molecular and clinical
analysis of cancer virtual cohorts. Nucleic Acids Res.
48:W463–W471. 2020.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Tang Z, Kang B, Li C, Chen T and Zhang Z:
GEPIA2: An enhanced web server for large-scale expression profiling
and interactive analysis. Nucleic Acids Res. 47:W556–W560.
2019.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Chandrashekar DS, Karthikeyan SK, Korla
PK, Patel H, Shovon AR, Athar M, Netto GJ, Qin ZS, Kumar S, Manne
U, et al: UALCAN: An update to the integrated cancer data analysis
platform. Neoplasia. 25:18–27. 2022.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Chandrashekar DS, Bashel B, Balasubramanya
SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK and
Varambally S: UALCAN: A portal for facilitating tumor subgroup gene
expression and survival analyses. Neoplasia. 19:649–658.
2017.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Győrffy B: Integrated analysis of public
datasets for the discovery and validation of survival-associated
genes in solid tumors. Innovation (Camb). 5(100625)2024.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Amin MB, Greene FL, Edge SB, Compton CC,
Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR and
Winchester DP: The eighth edition AJCC cancer staging manual:
Continuing to build a bridge from a population-based to a more
‘personalized’ approach to cancer staging. CA Cancer J Clin.
67:93–99. 2017.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Ushakov E, Naumov A, Fomberg V,
Vishnyakova P, Asaturova A, Badlaeva A, Tregubova A, Karpulevich E,
Sukhikh G and Fatkhudinov T: EndoNet: Model for automatic
calculation of H-score on histological slides. Informatics.
10(90)2023.
|
|
34
|
Bencze J, Szarka M, Kóti B, Seo W,
Hortobágyi TG, Bencs V, Módis LV and Hortobágyi T: Comparison of
semi-quantitative scoring and artificial intelligence aided digital
image analysis of chromogenic immunohistochemistry. Biomolecules.
12(19)2021.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Numata M, Morinaga S, Watanabe T, Tamagawa
H, Yamamoto N, Shiozawa M, Nakamura Y, Kameda Y, Okawa S, Rino Y,
et al: The clinical significance of SWI/SNF complex in pancreatic
cancer. Int J Oncol. 42:403–410. 2013.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Kim HY: Statistical notes for clinical
researchers: Chi-squared test and Fisher's exact test. Restor Dent
Endod. 42:152–155. 2017.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Wu JN and Roberts CW: ARID1A mutations in
cancer: Another epigenetic tumor suppressor? Cancer Discov.
3:35–43. 2013.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Jones S, Wang TL, Shih Ie M, Mao TL,
Nakayama K, Roden R, Glas R, Slamon D, Diaz LA Jr, Vogelstein B, et
al: Frequent mutations of chromatin remodeling gene ARID1A in
ovarian clear cell carcinoma. Science. 330:228–231. 2010.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Fujimoto A, Furuta M, Totoki Y, Tsunoda T,
Kato M, Shiraishi Y, Tanaka H, Taniguchi H, Kawakami Y, Ueno M, et
al: Whole-genome mutational landscape and characterization of
noncoding and structural mutations in liver cancer. Nat Genet.
48:500–509. 2016.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Mathur R, Alver BH, San Roman AK, Wilson
BG, Wang X, Agoston AT, Park PJ, Shivdasani RA and Roberts CW:
ARID1A loss impairs enhancer-mediated gene regulation and drives
colon cancer in mice. Nat Genet. 49:296–302. 2017.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Kadoch C, Hargreaves DC, Hodges C, Elias
L, Ho L, Ranish J and Crabtree GR: Proteomic and bioinformatic
analysis of mammalian SWI/SNF complexes identifies extensive roles
in human malignancy. Nat Genet. 45:592–601. 2013.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Cancer Genome Atlas Network. Comprehensive
molecular characterization of human colon and rectal cancer.
Nature. 487:330–337. 2012.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Bitler BG, Aird KM, Garipov A, Li H,
Amatangelo M, Kossenkov AV, Schultz DC, Liu Q, Shih IeM,
Conejo-Garcia JR, et al: Synthetic lethality by targeting EZH2
methyltransferase activity in ARID1A-mutated cancers. Nat Med.
21:231–238. 2015.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Zhu Y, Yan C, Wang X, Xu Z, Lv J, Xu X, Yu
W, Zhou M and Yue L: Pan-cancer analysis of ARID family members as
novel biomarkers for immune checkpoint inhibitor therapy. Cancer
Biol Ther. 23:104–111. 2022.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Jiang H, Cao HJ, Ma N, Bao WD, Wang JJ,
Chen TW, Zhang EB, Yuan YM, Ni QZ, Zhang FK, et al: Chromatin
remodeling factor ARID2 suppresses hepatocellular carcinoma
metastasis via DNMT1-Snail axis. Proc Natl Acad Sci USA.
117:4770–4780. 2020.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Odnokoz O, Wavelet-Vermuse C, Hophan SL,
Bulun S and Wan Y: ARID1 proteins: From transcriptional and
post-translational regulation to carcinogenesis and potential
therapeutics. Epigenomics. 13:809–823. 2021.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Xu S and Tang C: The Role of ARID1A in
tumors: Tumor initiation or tumor suppression? Front Oncol.
11(745187)2021.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Hu WH, Chen HH, Yen SL, Huang HY, Hsiao CC
and Chuang JH: Increased expression of interleukin-23 associated
with progression of colorectal cancer. J Surg Oncol. 115:208–212.
2017.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Erfani M, Hosseini SV, Mokhtari M, Zamani
M, Tahmasebi K, Alizadeh Naini M, Taghavi A, Carethers JM, Koi M,
Brim H, et al: Altered ARID1A expression in colorectal cancer. BMC
Cancer. 20(350)2020.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Baldi S, He Y, Ivanov I, Khamgan H, Safi
M, Alradhi M, Shopit A, Al-Danakh A, Al-Nusaif M, Gao Y and Tian H:
Aberrantly hypermethylated ARID1B is a novel biomarker and
potential therapeutic target of colon adenocarcinoma. Front Genet.
13(914354)2022.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Zhenzong T, Wang H and Peng Y: ARID2
suppresses cell proliferation, migration, and invasion of colon
cancer by the TGF-β1/Smad pathway. Journal of Biological Regulators
and Homeostatic Agents. 37:2095–2103. 2023.
|
|
52
|
Raab JR, Resnick S and Magnuson T:
Genome-Wide transcriptional regulation mediated by biochemically
distinct SWI/SNF complexes. PLoS Genet. 11(e1005748)2015.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Reddy D, Bhattacharya S and Workman JL:
(mis)-Targeting of SWI/SNF complex(es) in cancer. Cancer Metastasis
Rev. 42:455–470. 2023.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Zhao S, Wu W, Jiang Z, Tang F, Ding L, Xu
W and Ruan L: Roles of ARID1A variations in colorectal cancer: A
collaborative review. Mol Med. 28(42)2022.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Kishida Y, Oishi T, Sugino T, Shiomi A,
Urakami K, Kusuhara M, Yamaguchi K, Kitagawa Y and Ono H:
Associations between loss of ARID1A expression and
clinicopathologic and genetic variables in T1 early colorectal
cancer. Am J Clin Pathol. 152:463–470. 2019.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Cho HD, Lee JE, Jung HY, Oh MH, Lee JH,
Jang SH, Kim KJ, Han SW, Kim SY, Kim HJ, et al: Loss of tumor
suppressor ARID1A protein expression correlates with poor prognosis
in patients with primary breast cancer. J Breast Cancer.
18:339–346. 2015.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Namjan A, Techasen A, Loilome W,
Sa-Ngaimwibool P and Jusakul A: ARID1A alterations and their
clinical significance in cholangiocarcinoma. PeerJ.
8(e10464)2020.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Cui Y, Bai X, Niu M, Qin Y, Zhang X and
Pang D: Upregulated expression of AT-rich interactive
domain-containing protein 1B predicts poor prognosis in patients
with triple-negative breast cancer. Oncol Lett. 17:3289–3295.
2019.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Wu M, Duan Q, Liu X, Zhang P, Fu Y, Zhang
Z, Liu L, Cheng J and Jiang H: MiR-155-5p promotes oral cancer
progression by targeting chromatin remodeling gene ARID2. Biomed
Pharmacother. 122(109696)2020.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Fukumoto T, Park PH, Wu S, Fatkhutdinov N,
Karakashev S, Nacarelli T, Kossenkov AV, Speicher DW, Jean S, Zhang
L, et al: Repurposing Pan-HDAC inhibitors for ARID1A-mutated
ovarian cancer. Cell Rep. 22:3393–3400. 2018.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Helming KC, Wang X, Wilson BG, Vazquez F,
Haswell JR, Manchester HE, Kim Y, Kryukov GV, Ghandi M, Aguirre AJ,
et al: ARID1B is a specific vulnerability in ARID1A-mutant cancers.
Nat Med. 20:251–254. 2014.PubMed/NCBI View Article : Google Scholar
|
